ライフサイエンスコーパス: specific immunotherapy

1 serum concentrations enhances the benefit of specific immunotherapy.

2 igens and allergic patients before and after specific immunotherapy.

3 ) suggests this molecule as prime target for specific immunotherapy.

4 native to conventional subcutaneous allergen-specific immunotherapy.

5 gation to improve the efficacy and safety of specific immunotherapy.

6 ased in allergic patients receiving allergen-specific immunotherapy.

7 sponses to allergens and successful allergen-specific immunotherapy.

8 immunopathology and the clinical efficacy of specific immunotherapy.

9 ecules of P pratense previously proposed for specific immunotherapy.

10 ies, and have implications for diagnosis and specific immunotherapy.

11 prescribed routes for administering allergen-specific immunotherapy.

12 unctive therapy in conjunction with allergen-specific immunotherapy.

13 e gun has emerged as an important form of Ag-specific immunotherapy.

14 evaluated as immunogens to implement active specific immunotherapy.

15 nfiltrating T(reg) cells could enhance tumor-specific immunotherapy.

16 are distinguished by their susceptibility to specific immunotherapy.

17 a stratification factor targeted for active-specific immunotherapy.

18 boosting the patient's immune response using specific immunotherapy.

19 dditional evaluation as a target for antigen-specific immunotherapy.

20 nomas and also serves as a target for active-specific immunotherapy.

21 e assessment, antigen discovery, and antigen-specific immunotherapy.

22 that would normally escape killing by MART-1-specific immunotherapy.

23 malignancies and may be a target for antigen-specific immunotherapy.

24 vely, a tumor-associated antigen for active, specific immunotherapy.

25 d management and the development of allergen-specific immunotherapy.

26 solation of immunogenic antigens and antigen-specific immunotherapy.

27 otential targets for the induction of active specific immunotherapy.

28 is very important for the design of antigen-specific immunotherapy.

29 prostate cancers, is a potential target for specific immunotherapy.

30 can be used as potential targets for active-specific immunotherapy.

31 has been shown to be suppressed in allergen-specific immunotherapy.

32 and improved the efficacy of the checkpoint-specific immunotherapy.

33 allergen tolerance induction during allergen-specific immunotherapy.

34 ation that may serve as a target for TI Treg-specific immunotherapy.

35 d to the improvement of diagnosis as well as specific immunotherapy.

36 manipulated ex vivo, enables Ag- or patient-specific immunotherapy.

37 roteins can enhance the efficacy of allergen-specific immunotherapy.

38 tients during the build-up phase of allergen-specific immunotherapy.

39 promising vaccines for birch pollen allergen-specific immunotherapy.

40 kes Graves' disease a prime candidate for Ag-specific immunotherapy.

41 atitis, and malaria vaccines and in allergen-specific immunotherapy.

42 This is also the case for specific immunotherapy.

43 improve the efficacy and safety of allergen-specific immunotherapy.

44 itization and determine its role in allergen-specific immunotherapy.

45 agnosis and offer the possibility of antigen-specific immunotherapy.

46 be considered an important component for HDM-specific immunotherapy.

47 al failed to demonstrate clinical benefit of specific immunotherapy.

48 lergen-derived epitopes change over allergen-specific immunotherapy.

49 nding is one important mechanism of allergen-specific immunotherapy.

50 re anaphylaxis management plans and allergen-specific immunotherapy.

51 oinflammatory is important for the design of specific immunotherapies.

52 clinical trials of several specific and non-specific immunotherapies.

53 cytokines need to be explored to design more specific immunotherapies.

54 esis of PV, with implications for developing specific immunotherapies.

55 hich there is an unmet need for antigen (Ag)-specific immunotherapies.

56 ploited to develop in vivo imaging and islet-specific immunotherapies.

57 are a first step towards developing peptide-specific immunotherapies.

58 ze neoantigens for individualized neoantigen-specific immunotherapies.

59 ablished as a novel mechanism to escape CD19-specific immunotherapies.

60 Specific immunotherapy acts to modify the underlying cau

61 LT may be a promising strategy for allergen-specific immunotherapy against birch pollen allergy.

62 linical and clinical studies as a target for specific immunotherapy against gastrointestinal adenocar

63 ed to evaluate CEA as a potential target for specific immunotherapy against HNC.

64 n be further developed as patient- and tumor-specific immunotherapy against human lymphomas.

65 in patients with malignant glioma by active specific immunotherapy against these common MAAs.

66 disease pathogenesis and test novel TSHR Ag-specific immunotherapies aimed at curing Graves' disease

67 sing therapeutic approaches such as allergen-specific immunotherapy (AIT) for allergic asthma and bio

68 Molecular forms of allergen-specific immunotherapy (AIT) for cat allergy are needed.

69 Allergen-specific immunotherapy (AIT) has advantages over symptom

70 nd easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poo

71 Allergen-specific immunotherapy (AIT) has been used for more than

72 ry B (Breg) cell development during allergen-specific immunotherapy (AIT) has not been reported.

73 Allergen-specific immunotherapy (AIT) induces immune tolerance, s

74 Allergen-specific immunotherapy (AIT) induces specific blocking a

75 Allergen-specific immunotherapy (AIT) is an allergen-specific for

76 ed mostly to relieve symptoms, only allergen-specific immunotherapy (AIT) is targeted to modify the n

77 Allergen-specific immunotherapy (AIT) is the only available cause

78 Allergen-specific immunotherapy (AIT) is the only causal treatmen

79 Allergen-specific immunotherapy (AIT) is the only disease-modifyi

80 Allergen-specific immunotherapy (AIT) is the only disease-modifyi

81 Allergen-specific immunotherapy (AIT) is the only means of alteri

82 Allergen-specific immunotherapy (AIT) is the single therapeutic s

83 While allergen-specific immunotherapy (AIT) is very efficient in hymeno

84 To cure these allergic diseases, allergen-specific immunotherapy (AIT) represents the unique treat

85 a double-blind, placebo-controlled allergen-specific immunotherapy (AIT) study indicated that patien

86 alth care cost savings conferred by allergen-specific immunotherapy (AIT) to US children with allergi

87 m a double-blind placebo-controlled allergen-specific immunotherapy (AIT) trial using sublingual 300

88 It is still unclear whether allergen-specific immunotherapy (AIT) with birch pollen improves

89 sed to induce allergen tolerance in allergen-specific immunotherapy (AIT), although mechanistic side-

90 global, allergome-wide level during allergen-specific immunotherapy (AIT).

91 ant in long-term treatment, such as allergen-specific immunotherapy (AIT).

92 ) 2 cells decrease after successful allergen-specific immunotherapy (AIT).

93 nnan (PM) are suitable vaccines for allergen-specific immunotherapy (AIT).

94 roposed as an alternative route for allergen-specific immunotherapy (AIT).

95 In the practice of antigen-specific immunotherapy, allergens or self antigens are r

96 Antigen-specific immunotherapy, an approach to selectively block

97 important implications for designing antigen-specific immunotherapies and identifying individuals tha

98 n is also crucial for the pursuit of antigen-specific immunotherapies and implementation of strategie

99 s the principle effector modality induced by specific immunotherapy and advances in antigen-carrier d

100 sources for refined prescription of allergen-specific immunotherapy and allergen avoidance diagnosis

101 ise for treating tumors by combining antigen-specific immunotherapy and antiangiogenesis.

102 Allergen-specific immunotherapy and biologic therapies that targe

103 mmunomodulatory treatments, such as allergen-specific immunotherapy and biologicals.

104 appear to play an important role in allergen-specific immunotherapy and could be an attractive target

105 basophils has been demonstrated in allergen-specific immunotherapy and drug desensitization.

106 actions are common in the course of allergen-specific immunotherapy and even occur with allergy vacci

107 As demonstrated in allergen-specific immunotherapy and in the healthy immune respons

108 OS and RFS achieved by active specific immunotherapy and low-dose IFN-alpha-2b were in

109 ected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (

110 e findings support further development of E7-specific immunotherapy and strategies for up-regulation

111 allergic reactions, but advances in allergen-specific immunotherapy and the development of biologics

112 e articles focused on mechanisms of allergen-specific immunotherapy and the development of novel anti

113 Th response to K as a key step in designing specific immunotherapy and understanding the immunogenic

114 including the role of next-generation target-specific immunotherapies, and (3) provide a practical fr

115 me, identify patients likely to benefit from specific immunotherapies, and tailor combination immunot

116 ed since the first report describing antigen-specific immunotherapy (antigen-SIT) was published.

117 new drugs are already available and antigen-specific immunotherapies are being developed.

118 Improved methods of delivering peanut-specific immunotherapy are needed.

119 This promotes epitope specific immunotherapy as a possible safe treatment opti

120 nd we put forth the concept of focused organ-specific immunotherapy as an alternative option.

121 their increase during the course of allergen-specific immunotherapy, as well as their increased expre

122 Antigen-specific immunotherapy (ASI) has been proposed as an alt

123 The aim for antigen-specific immunotherapy (ASI) is to restore tolerance.

124 des currently being investigated for antigen specific immunotherapy (ASI) of type 1 diabetes.

125 phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor ce

126 There are currently no approved antigen-specific immunotherapies (ASIs) for people with type 1 d

127 st in testing whether the success of antigen-specific immunotherapy (ASIT) for autoimmune diseases in

128 Allergen-specific immunotherapy (ASIT) is used to treat the sympt

129 Antigen-specific immunotherapy (ASIT) offers a targeted treatmen

130 Successful antigen-specific immunotherapy (ASIT) would allow for improved t

131 the use as adjuvant and carrier in allergen-specific immunotherapy (ASIT).

132 of the major fish allergen, parvalbumin, for specific immunotherapy based on mutation of the 2 calciu

133 pment of a vaccine for grass pollen allergen-specific immunotherapy based on two recombinant hypoalle

134 n conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase

135 However, subcutaneous allergen-specific immunotherapy can also induce anaphylaxis in so

136 Antigen-specific immunotherapy can be limited by induced tumor i

137 Specific immunotherapy can greatly reduce the need for s

138 time, direct evidence in humans that antigen-specific immunotherapy can target not only antigen-posit

139 for multiple rV-CEA immunizations in active-specific immunotherapy clinical protocols directed at CE

140 Antigen-specific immunotherapy combats autoimmunity or allergy b

141 Development of tolerogenic, antigen-specific immunotherapies could overcome limitations of e

142 Active-specific immunotherapy could induce and/or augment the T

143 e of ALK(+) tumours, together with potent or specific immunotherapies, could achieve this goal.

144 RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific soma

145 een made through the development of allergen-specific immunotherapy encompassing 3 major forms of tre

146 Recently, epicutaneous allergen-specific immunotherapy (EPIT) has proven effective, yet

147 Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an alternat

148 of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will be presented and disc

149 Epicutaneous allergen-specific immunotherapy (EPIT) with OVA and DCP also prot

150 ith mRNA isolated from tumor cells may allow specific immunotherapy even in cancers for which potent

151 effective immune modulator in several active-specific immunotherapy experimental protocols using eith

152 The seventh "Future of the Allergists and Specific Immunotherapy (FASIT)" workshop held in 2019 pr

153 that arise postvaccination and following Ag-specific immunotherapies for cancer and autoimmune disea

154 in using this phenomenon to develop antigen-specific immunotherapies for T cell-mediated autoimmune

155 nesis and for the rational development of Ag-specific immunotherapies for the disease.

156 tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tum

157 ant epitope may allow development of antigen-specific immunotherapy for CD.

158 tential approach of tumor-specific G antigen-specific immunotherapy for cervical cancer.

159 Although specific immunotherapy for food allergies is becoming mo

160 pened unprecedented opportunities for active specific immunotherapy for melanoma with synthetic pepti

161 These findings describe a promising specific immunotherapy for patients with DR1-mediated au

162 To date, no safe allergen-specific immunotherapy for patients with peanut allergy

163 od hypersensitivities worldwide but allergen-specific immunotherapy for shellfish allergy is not yet

164 Subcutaneous allergen-specific immunotherapy frequently causes allergic side e

165 Allergen specific immunotherapy has been shown to be the only eff

166 Allergen-specific immunotherapy has shown promise for the treatme

167 New strategies in allergen-specific immunotherapy have also emerged, such as the us

168 New strategies for allergen-specific immunotherapy have focused on reducing IgE reac

169 this multi-component, plasmid-based antigen-specific immunotherapy holds potential for inducing self

170 Thus, antigen-specific immunotherapy holds promise for strengthening i

171 ells and therefore is a promising target for specific immunotherapies in AML.

172 aise important considerations for the use of specific immunotherapies in general.

173 m and tumours and enable evaluation of human-specific immunotherapies in vivo is limited.

174 Importantly, successful specific immunotherapy in allergic patients also induced

175 enting a novel option for improving allergen-specific immunotherapy in Alternaria allergy.

176 TL clones are promising reagents for antigen-specific immunotherapy in BMT hosts, because they engraf

177 n landscape were observed following allergen-specific immunotherapy in cT(FH) and T(FR) cells.

178 nd LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC.

179 -NPs might be a valuable strategy for peanut-specific immunotherapy in human subjects.

180 implications for clinical approaches to CTAg-specific immunotherapy in patients with cancer.

181 sents a useful immunogen to implement active specific immunotherapy in patients with melanoma, becaus

182 eactive serum IgGs after successful allergen-specific immunotherapy in patients.

183 The efficacy of single-allergen-specific immunotherapy in polysensitized subjects is a m

184 o induce immune deviation by mucosal peptide-specific immunotherapy in rheumatoid arthritis (RA) pati

185 ith malignant melanoma, vitiligo, and active-specific immunotherapy-induced depigmentation had signif

186 d to monitor the blocking effect of allergen-specific immunotherapy-induced non-IgE antibodies.

187 Induction of allergen tolerance through specific immunotherapy induces a specific expansion of t

188 Allergen-specific immunotherapy induces a yet unknown local gene

189 Allergen-specific immunotherapy inhibited pro-inflammatory CXCL8,

190 Many forms of specific immunotherapy involve the administration of all

191 Grass pollen-specific immunotherapy involves immunomodulation of alle

192 Antigen-specific immunotherapy involves the delivery of self-ant

193 A major challenge facing antigen-specific immunotherapies is ineffective control over imm

194 Allergen-specific immunotherapy is a disease-modifying treatment

195 Ag-specific immunotherapy is a long-term goal for the treat

196 Subcutaneous allergen-specific immunotherapy is a standard route for the immun

197 Sublingual allergen-specific immunotherapy is a viable alternative to subcut

198 r, neither a protective vaccine nor pathogen-specific immunotherapy is currently available.

199 Allergen-specific immunotherapy is helpful in IgE-mediated AR and

200 Allergen-specific immunotherapy is not currently undertaken for p

201 Allergen-specific immunotherapy is offered in 39% (60/154) of ser

202 Efficacy of allergen-specific immunotherapy is often severely impaired by det

203 The main aim of specific immunotherapy is sustained effect due to change

204 The goal of allergen-specific immunotherapy is the induction of protective im

205 Allergen-specific immunotherapy is the only allergen-specific and

206 Allergen-specific immunotherapy is the only causative treatment o

207 Allergen-specific immunotherapy is the only curative treatment fo

208 Allergen-specific immunotherapy is the only known therapy that pr

209 Allergen-specific immunotherapy is the only mode of therapy that

210 Allergen-specific immunotherapy is the only treatment shown to mo

211 An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the battl

212 Finally, specific immunotherapy is under further investigation as

213 Human studies demonstrated that allergen-specific immunotherapy (IT) represents an effective trea

214 ponse of vitamin D as an adjunct to allergen-specific immunotherapy (IT).

215 Allergen-specific immunotherapy may be considered in cases of fai

216 iotics have not proved helpful, but allergen-specific immunotherapy may be disease modifying and ther

217 Antigen specific immunotherapy mediated via the sustained genera

218 on the clinical development of products for specific immunotherapy of allergic diseases do not adequ

219 tes immunotolerance, as, for example, during specific immunotherapy of allergies, but it mediates tis

220 epresents a highly interesting candidate for specific immunotherapy of birch pollen allergy.

221 prompted renewed efforts to develop antigen-specific immunotherapy of cancer.

222 s a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradig

223 be an essential component for diagnosis and specific immunotherapy of HDM allergy.

224 inant hypoallergenic combination vaccine for specific immunotherapy of HDM allergy.

225 in developing efficient vaccines for antigen-specific immunotherapy of human malignancies.

226 To develop a specific immunotherapy of MG, we treated rats with ongoi

227 ign an altered peptide ligand, CGP77116, for specific immunotherapy of multiple sclerosis.

228 en Bos d 9-specific B cells in oral allergen-specific immunotherapy (OIT) and in children spontaneous

229 In contrast, the effect of allergen-specific immunotherapy on allergic inflammation is compl

230 t be helpful to evaluate the effect of birch-specific immunotherapy on pollen-associated food allergi

231 ng T(H)2 cells and the influence of allergen specific immunotherapy on the phenotype and function of

232 rameters influencing the efficacy of antigen-specific immunotherapy once diabetes is established, pla

233 tant IgE epitopes can be induced by allergen-specific immunotherapy or by passive immunization.

234 riven approaches as contributing to allergen-specific immunotherapy outcomes, but understanding of ho

235 inistration of 25(OH)D in the context of OVA-specific immunotherapy reduced the allergic airway infla

236 OVA-specific immunotherapy reduced the humoral immune reacti

237 he mechanistic underpinnings for compartment-specific immunotherapy-responsiveness and suggest that p

238 Finally, specific immunotherapy resulted in IL-5 down modulation,

239 Subcutaneous allergen-specific immunotherapy (SCIT) is a well-documented treat

240 native to conventional subcutaneous allergen-specific immunotherapy (SCIT).

241 These findings suggest that adjuvant active specific immunotherapy should be considered after cytore

242 Although subcutaneous allergen-specific immunotherapy showed no statistically significa

243 This antigen-specific immunotherapy significantly reduced both the in

244 Early events of specific immunotherapy (SIT) are induction of allergen-s

245 Allergen-specific immunotherapy (SIT) faces problems related to s

246 lay a critical role in subcutaneous allergen-specific immunotherapy (SIT) for atopic dermatitis (AD).

247 ating the role of CD4(+) T cells in allergen-specific immunotherapy (SIT) has been the absence of an

248 Specific immunotherapy (SIT) involves repeated treatment

249 Specific immunotherapy (SIT) is an effective long-term t

250 Specific immunotherapy (SIT) is the most widely used tre

251 Specific immunotherapy (SIT) is the only treatment with

252 ere matched against an experimental allergen-specific immunotherapy (SIT) preparation containing Phl

253 cross-reacting molecules might hinder proper specific immunotherapy (SIT) prescription in polysensiti

254 Specific immunotherapy (SIT) represents an effective tre

255 he most effective treatment for allergies is specific immunotherapy (SIT), which involves the injecti

256 populations in patients with allergies after specific immunotherapy (SIT).

257 mbinant allergens offer a tool for improving specific immunotherapy (SIT).

258 IgE- and T-cell-mediated side-effects during specific immunotherapy (SIT).

259 uisite for accurate prescription of allergen-specific immunotherapy (SIT).

260 from a patient who had received grass pollen-specific immunotherapy (SIT).

261 Sublingual allergen-specific immunotherapy (SLIT) intervention improves the

262 lar diagnosis of, and for the development of specific immunotherapy strategies against, wheat food al

263 y considerations for next-generation antigen-specific immunotherapies targeting autoimmune disease.

264 nhibited in standard NOD mice by autoantigen-specific immunotherapy targeting pathogenic CD8+ T-cells

265 00E) would suggest the feasibility of active specific immunotherapy targeting the mutation in these p

266 opportunity to subvert CMV antigens as tumor-specific immunotherapy targets.

267 sed as a safer hypoallergenic alternative in specific immunotherapy than the pollen extracts used tod

268 er a promising path for developing DC subset-specific immunotherapies that cannot be provided by tran

269 In 18 patients treated by Bet v 1-fragment-specific immunotherapy, the effects of IgG antibodies sp

270 Antigen-specific immunotherapy therefore offers disease interven

271 downregulated to some degree by conventional specific immunotherapy, this approach is only partially

272 providing a novel islet-targeted and antigen-specific immunotherapy to prevent and reverse clinical T

273 e alloislet transplantation represents an Ag-specific immunotherapy to resolve autoimmune diabetes in

274 e alloislet transplantation represents an Ag-specific immunotherapy to resolve autoimmune diabetes in

275 Ag-specific immunotherapy to restore immune tolerance to se

276 onitoring the therapeutic efficacy of active specific immunotherapy toward specific MAA-bearing melan

277 Responses from specific immunotherapy treatment individuals were weaker

278 a function of seasonality, or as a result of specific immunotherapy treatment or varying disease seve

279 rine administration because current allergen-specific immunotherapy treatments are limited by adverse

280 evaluate the efficacy and safety of allergen-specific immunotherapy using 2 dose regimens of Bet v 1

281 -gamma: Antitumor immunity induced by active-specific immunotherapy (vaccination) required IFN-gamma,

282 dress these limitations, adjunctive allergen-specific immunotherapy, vaccines, and non-allergen-speci

283 Allergen-specific immunotherapy via the skin targets a tissue ric

284 Specific immunotherapy via the subcutaneous or oral rout

285 Venom-specific immunotherapy (VIT) is well recognized by its e

286 Allergen-specific immunotherapy was associated with preferential

287 OVA-specific immunotherapy was established and studied in a

288 Active specific immunotherapy was injected subcutaneously (SC)

289 aspects of various antigen-specific and non-specific immunotherapies, which could potentially preven

290 r lymphocyte depletion prior to oral antigen-specific immunotherapy will likely be required to impart

291 sion emphasizes the need to implement active specific immunotherapy with a combination of peptides pr

292 dies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi c

293 eive either 2 years of treatment with active specific immunotherapy with allogeneic melanoma lysates

294 Specific immunotherapy with birch pollen (BP-SIT) induce

295 However, specific immunotherapy with birch pollen has inconsisten

296 Active-specific immunotherapy with dendritic cells loaded with

297 Allergen-specific immunotherapy with depigmented HDM extract via

298 Allergen-specific immunotherapy with SHAS-OVA as compared to solu

299 efficacy and safety of subcutaneous allergen-specific immunotherapy with the use of depigmented polym

300 er-reactivity can be achieved using allergen-specific immunotherapy without significant reductions in